A year after CRL, Acadia is going back to bat for Nuplazid at the FDA

A potential blockbuster drug for Acadia Pharmaceuticals is facing a new round of FDA scrutiny in June.

The FDA is holding a public advisory committee meeting on June 17 to discuss a supplemental new drug application for Nuplazid to treat hallucinations and delusions associated with Alzheimer’s disease psychosis.